KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBIT (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of EBIT data on record, last reported at $254.5 million in Q4 2025.

  • For Q4 2025, EBIT rose 33.43% year-over-year to $254.5 million; the TTM value through Dec 2025 reached $19.1 million, down 97.33%, while the annual FY2025 figure was -$430.2 million, 160.04% down from the prior year.
  • EBIT reached $254.5 million in Q4 2025 per JAZZ's latest filing, up from -$686.4 million in the prior quarter.
  • Across five years, EBIT topped out at $260.2 million in Q3 2024 and bottomed at -$686.4 million in Q2 2025.
  • Average EBIT over 5 years is $53.8 million, with a median of $105.0 million recorded in 2022.
  • Peak YoY movement for EBIT: plummeted 633.39% in 2022, then skyrocketed 596.17% in 2023.
  • A 5-year view of EBIT shows it stood at $49.4 million in 2021, then tumbled by 633.39% to -$263.4 million in 2022, then surged by 146.51% to $122.5 million in 2023, then soared by 55.73% to $190.8 million in 2024, then skyrocketed by 33.43% to $254.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $254.5 million in Q4 2025, -$686.4 million in Q2 2025, and $190.8 million in Q4 2024.